Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 292, Issue 6, 2007, Pages

  Ma, Kun L ^a   Ruan, Xiong Z ^a   Powis, Stephen H ^a   Moorhead, John F ^a   Varghese, Zac ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cholesterol homeostasis; Foam cell; Inflammatory cytokine

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A1; BREAST CANCER RESISTANCE PROTEIN; CHOLESTEROL; CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; RAPAMYCIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HOMEOSTASIS; HUMAN; HUMAN CELL; LIPID STORAGE; MEASUREMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; STAINING; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

ATHEROSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; AZO COMPOUNDS; CARDIOVASCULAR AGENTS; CELLS, CULTURED; CHOLESTEROL; COLORING AGENTS; CORONARY VESSELS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; HOMEOSTASIS; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; RECEPTORS, LDL; RNA, MESSENGER; SIROLIMUS; STAINING AND LABELING;

EID: 34447530621     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01174.2006     Document Type: Article

References (46)

1. Basso MD, Nambi P, Adelman SJ. Effect of sirolimus on the cholesterol content of aortic arch in ApoE knockout mice. Transplant Proc 35: 3136-3138, 2003.
2. -/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394: 894-897, 1998.
3. Castro C, Campistol JM, Sancho D, Sanchez-Madrid F, Casals E, Andres V. Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1 -independent pathway. Atherosclerosis 172: 31-38, 2004.
4. Clowes AW Schwartz SM. Significance of quiescent smooth muscle migration in the injured rat carotid artery. Circ Res 56: 139-145, 1985.
5. Degertekin M, Regar E, Tanabe K, Lee CH, Serruys PW. Sirolimus eluting stent in the treatment of atherosclerosis coronary artery disease. Minerva Cardioangiol 50: 405-418, 2002.
6. Dong ZM, Chapman SM, Brown AA, Frenette PS, Hynes RO, Wagner DD. The combined role of P- and E-selectins in atherosclerosis. J Clin Invest 102: 145-152, 1998.
7. Elloso MM, Azrolan N, Sehgal SN, Hsu PL, Phiel KL, Kopec CA, Basso MD, Adelman SJ. Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo e-deficient mice. Am J Transplant 3: 562-569, 2003.
8. Galea J, Armstrong J, Gadsdon P, Holden H, Francis SE, Holt CM. Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arteriosclerosis Thrombosis Vasc Biol 16: 1000-1006, 1996.
9. Gallo R, Padurean A, Jayaraman T, Marx S, Roque M, Adelman S, Chesebro J, Fallon J, Fuster V, Marks A, Badimon JJ. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 99: 2164-2170, 1999.
10. Gamble W, Vaughan M, Kruth HS, Avigan J. Procedure for determination of free and total cholesterol in micro- or nanogram amounts suitable for studies with cultured cells. J Lipid Res 19: 1068-1070, 1978.
11. Greaves DR Channon KM. Inflammation and immune responses in atherosclerosis. Trends Immunol 23: 535-541, 2002.
12. Gregory CR, Huie P, Billingham ME, Morris RE. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels. Transplantation 55: 1409-1418, 1993.
13. Hoogeveen RC, Ballantyne CM, Pownall HJ, Opekun AR, Hachey DL, Jaffe JS, Oppermann S, Kahan BD, Morrisett JD. Effect of sirolimus on the metabolism of ApoB100-containing lipoproteins in renal transplant patients. Transplantation 72: 1244-1250, 2001.
14. Kaul D. Molecular link between cholesterol, cytokines and atherosclerosis. Mol Cell Biochem 219: 65-71, 2001.
15. Lemos PA, Regar E, Serruys PW. Drug-eluting stents in the treatment of atherosclerotic coronary heart disease. Indian Heart J 54: 212-216, 2002.
16. Libby P. Inflammation in atherosclerosis. Nature 420: 868-874, 2002.
17. Lu LF Fiscus RR. Interleukin-1[beta] causes different levels of nitric oxide-mediated depression of contractility in different positions of rat thoracic aorta. Life Sci 64: 1373-1381, 1999.
18. Martin KA, Rzucidlo EM, Merenick BL, Fingar DC, Brown DJ, Wagner RJ, Powell RJ. The mTOR/p70 S6K1 pathway regulates vascular smooth cell differentiation. Am J Physiol Cell Physiol 286: C507-C517, 2004.
19. Merhi-Soussi F, Kwak BR, Magne D, Chadjichristos C, Berti M, Pelli G, James RW, Mach F, Gabay C. Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc Res 66: 583-593, 2005.
20. Morales JM. Cardiovascular risk profile in patients treated with sirolimus after renal transplantation. Kidney Int 67: S69-S73, 2005.
21. Morris RE, Cao W, Huang X, Gregory CR, Billingham ME, Rowan R, Shorthouse RA. Rapamycin (Sirolimus) inhibits vascular smooth muscle DNA synthesis in vitro and suppresses narrowing in arterial allografts and in balloon-injured carotid arteries: evidence that rapamycin antagonizes growth factor action on immune and nonimmune cells. Transplant Proc 27: 430-431, 1995.
22. Morrisett JD, Abdel-Fattah G, Hoogeveen R, Mitchell E, Ballantyne CM, Pownall HJ, Opekun AR, Jaffe JS, Oppermann S, Kahan BD. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 43: 1170-1180, 2002.
23. Morrisett JD, Abdel-Fattah G, Kahan BD. Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplant Proc 35: 143S-150S, 2003.
24. Morrisett JD, Abdel-Fattah G, Kahan BD. Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplant Proc 35: 143S-150S, 2003.
25. Moyer CF, Sajuthi D, Tulli H, Williams JK. Synthesis of Il-1 Alpha and Il-1 Beta by Arterial Cells in Atherosclerosis. Am J Pathol 138: 951-960, 1991.
26. Naoum JJ, Woodside KJ, Zhang S, Rychahou PG, Hunter GC. Effects of rapamycin on the arterial inflammatory response in atherosclerotic plaques in Apo-E knockout mice. Transplant Proc 37: 1880-1884, 2005.
27. Naoum JJ, Zhang S, Woodside KJ, Song W, Guo Q, Belalcazar LM, Hunter GC. Aortic eNOS expression and phosphorylation in Apo-E knockout mice: differing effects of rapamycin and simvastatin. Surgery 136: 323-328, 2004.
28. Oliveira JGG, Xavier P, Sampaio SM, Henriques C, Tavares I, Mendes AA, Pestana M. Compared to mycophenolate mofetil, rapamycin induces significant changes on growth factors and growth factor receptors in the early days postkidney transplantation. Transplantation 73: 915-920, 2002.
29. Pakala R, Stabile E, Dang GJ, Clavijo L, Waksman R. Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice. Inhibitory effect on monocyte chemotaxis. J Cardiovasc Pharmacol 46: 481-486, 2005.
30. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB,. Marks AR. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 98: 2277-2283, 1996.
31. Rong JX, Shapiro M, Trogan E, Fisher EA. Transdifferentiation of mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading. Proc Natl Acad Sci USA 100: 13531-13536, 2003.
32. Rosenfeld ME Ross R. Macrophage and smooth muscle cell proliferation in atherosclerotic lesions of WHHL and comparably hypercholesterolemic fat-fed rabbits. Areriosclerosis 10: 680-687, 1990.
33. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115-126, 1999.
34. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362: 801-809, 1993.
35. Ruan XZ, Moorhead JF, Fernando R, Wheeler DC, Powis SH, Varghese Z. PPAR agonists protect mesangial cells from interleukin 1beta-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway. J Am Soc Nephrol 14: 593-600, 2003.
36. Ruan XZ, Moorhead JF, Tao JL, Ma KL, Wheeler DC, Powis SH, Varghese Z. Mechanisms of dysregulation of low-density lipoprotein receptor expression in vascular smooth muscle cells by inflammatory cytokines. Arterioscler Thromb Vasc Biol 5: 1150-1155, 2006.
37. Ruan XZ, Varghese Z, Moorhead JF. Inflammation modifies lipid-mediated renal injury. Nephrol Dial Transplant 18: 27-32, 2003.
38. Ruan XZ, Varghese Z, Powis SH, Moorhead JF. Human mesangial cells express inducible macrophage scavenger receptor. Kidney Int 56: 440-451, 1999.
39. Ruan XZ, Varghese Z, Powis SH, Moorhead JF. Dysregulation of LDL receptor under the influence of inflammatory cytokines: a new pathway for foam cell formation. Kidney Int 60: 1716-1725, 2002.
40. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt G. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 362: 1093-1099, 2003.
41. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci USA 92: 8264-8268, 1995.
42. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM, Seixas AC, Staico R, Mattos LA, Sousa AG, Falotico R, Jaeger J, Popma JJ, Serruys PW. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 103: 192-195, 2001.
43. Tousoulis D, Antoniades C, Koumallos N, Stefanadis C. Pro-inflammatory cytokines in acute coronary syndromes: from bench to bedside. Cytokine Growth Factor Rev 17: 225-233, 2006.
44. Varghese Z, Fernando R, Moorhead JF, Powis SH, Ruan XZ. Effects of sirolimus on mesangial cell cholesterol homeostasis: a novel mechanism for its action against lipid-mediated injury in renal allografts. Am J Physiol Renal Physiol 289: F43-F48, 2005.
45. Wasowska BA, Zheng XX, Strom TB, Kupiec-Weglinski JW. Adjunctive rapamycin and CsA treatment inhibits monocyte/macrophage associated cytokines/chemokines in sensitized cardiac graft recipients. Transplantation 71: 1179-1183, 2001.
46. Wolfbauer G, Glick JM, Minor LK, Rothblat GH. Development of the smooth muscle foam cell: uptake of macrophage lipid inclusions. Proc Natl Acad Sci USA 83: 7760-7764, 1986.